HLS Therapeutics Inc - Asset Resilience Ratio
HLS Therapeutics Inc (HLS) has an Asset Resilience Ratio of 10.13% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read HLS current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2022)
This chart shows how HLS Therapeutics Inc's Asset Resilience Ratio has changed over time. See operational self-sufficiency of HLS Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down HLS Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is HLS Therapeutics Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$21.81 Million | 10.13% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$21.81 Million | 10.13% |
Asset Resilience Insights
- Moderate Liquidity: HLS Therapeutics Inc has 10.13% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
HLS Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare HLS Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for HLS Therapeutics Inc (2001–2022)
The table below shows the annual Asset Resilience Ratio data for HLS Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 8.58% | CA$20.72 Million ≈ $14.99 Million |
CA$241.65 Million ≈ $174.81 Million |
+0.90pp |
| 2021-12-31 | 7.68% | CA$21.18 Million ≈ $15.32 Million |
CA$275.90 Million ≈ $199.59 Million |
+0.89pp |
| 2020-12-31 | 6.78% | CA$20.61 Million ≈ $14.91 Million |
CA$303.91 Million ≈ $219.84 Million |
-7.94pp |
| 2019-12-31 | 14.73% | CA$47.08 Million ≈ $34.06 Million |
CA$319.67 Million ≈ $231.25 Million |
+11.16pp |
| 2018-12-31 | 3.57% | CA$10.93 Million ≈ $7.91 Million |
CA$306.43 Million ≈ $221.66 Million |
-5.85pp |
| 2017-12-31 | 9.42% | CA$36.22 Million ≈ $26.20 Million |
CA$384.65 Million ≈ $278.25 Million |
+9.05pp |
| 2003-12-31 | 0.37% | CA$153.46K ≈ $111.01K |
CA$41.49 Million ≈ $30.01 Million |
-0.24pp |
| 2002-12-31 | 0.61% | CA$173.60K ≈ $125.58K |
CA$28.64 Million ≈ $20.72 Million |
+0.04pp |
| 2001-12-31 | 0.57% | CA$171.84K ≈ $124.31K |
CA$30.37 Million ≈ $21.97 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more